Findings from the 6-year follow-up of the ELEVATE-TN study demonstrated that the safety and efficacy of acalabrutinib with or without obinutuzumab was maintained among patients with treatment-naïve chronic lymphocytic leukemia, including those with high-risk genetic features.
December 11, 2023
Read moreIn the evolving landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treatment, a comprehensive cohort study conducted at the Mayo Clinic has shed light on the incidence of Richter transformation (RT). The study was presented at the 65th ASH Annual Meeting and Exposition held from December 9-12, 2023 (Abstract 3271).
December 11, 2023
Read moreIbrutinib plus venetoclax significantly improved responses, progression-free survival (PFS), and overall survival (OS) compared to standard chemoimmunotherapy in fit patients with previously untreated chronic lymphocytic leukemia (CLL). Among patients with newly diagnosed CLL who were treated with the two targeted agents and whose duration of treatment was determined by high-sensitivity testing for residual cancer cells in the blood, 97.2 percent were free of cancer progression and 2 percent had died at 3 years. In comparison, PFS for patients receiving the standard of care was 76.8 percent with a death rate of 7 percent.
December 11, 2023
Read moreReal-world findings suggest that a flexible dosing strategy for ibrutinib may be an effective option for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the first-line setting. These findings were recently presented by study author Nilanjan Ghosh, MD, PhD, Atrium Health Levine Cancer Institute, Charlotte, NC, during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9-12 in San Diego (Abstract 270).
December 10, 2023
Read moreIn the pursuit of more effective therapies for B-cell malignancies, a new Phase Ib study is underway, exploring the potential of AS-1763, a promising oral, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. The progress of the study was presented at the 65th ASH Annual Meeting and Exposition held December 9-12, 2023 (Abstract 3288).
December 10, 2023
Read moreA recent study found that chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients who had a dose reduction following an adverse event remained on first-line ibrutinib longer when compared to those who did not have a dose reduction. These findings were recently presented during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9-12 in San Diego (Abstract 269).
December 10, 2023
Read moreAt a median follow-up of 3 years, data from the Phase III ALPINE study showed sustained progression-free survival (PFS) benefits of zanubrutinib when compared to ibrutinib among patients with relapsed/refractory chronic lymphocytic leukemia.
December 9, 2023
Read moreA recent study, which took a closer look at the adoption of therapy options for chronic lymphocytic leukemia, identified a need for increased awareness of clinical treatment guidelines. These findings were recently presented during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9-12 in San Diego (Abstract 130).
December 9, 2023
Read moreLong-term outcome data from a Phase II study demonstrated the durable benefit of single-agent ibrutinib among patients with chronic lymphocytic leukemia (CLL), according to findings presented during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9-12 in San Diego (Abstract 201).
December 9, 2023
Read more